Abbvie
3Q Revenues: $14.5 billion (+4%)
3Q Earnings: $1.6 billion (-12%)
YTD Revenues: $41.2 billion (+3%) 
YTD Earnings: $4.3 billion (+6%)
Comments: Humira sales were $2.2 billion, down 37% in the quarter. Skyrizi sales were $3.2 billion, an increase of 51%. Rinvoq revenues were $1.6 billion, up 45%. Imbruvica sales were $828 million, down 9%. Venclexta sales were $677 million, up 15%.Elahere sales were $139 million. Botox Therapeutic sales were $848 million, up 13%. Vraylar revenues were $875 million, an increase of 17%. Ubrelvy sales were $269 million, an increase of 15%, and Qulipta sales were $176 million, up 34%. Botox Cosmetic revenues were $671 million, up 8%. Juvederm sales were down 20% to $258 million. Abbvie recently completed its acquisition of Cerevel, adding a pipeline of complementary assets to its neuroscience portfolio.